Simčič Petra, Pierini Alessio, Lubas George, Lowe Ron, Granziera Valentina, Tornago Raimondo, Valentini Fabio, Alterio Giulia, Cochi Matteo, Rangel Marcelo Monte Mor, de Oliveira Krishna Duro, Ostrand Freytag Jennifer, Quadros Priscila Gil, Sponza Enrico, Gattino Francesca, Impellizeri Joseph A, Torrigiani Filippo
Department of Veterinary Sciences, University of Pisa, Via Livornese Lato Monte, San Piero a Grado, 56122 Pisa, Italy.
PetCancerVet, 61 Wetherby Road, Knaresborough, North Yorkshire HG5 8LH, UK.
Vet Sci. 2021 Mar 22;8(3):53. doi: 10.3390/vetsci8030053.
Feline squamous cell carcinoma (SCC) is currently treated with surgery, radiation therapy and electrochemotherapy (ECT). Both the efficacy and/or safety of ECT were evaluated as a sole therapy with bleomycin to treat feline nasal planum SCC (npSCC). Sixty-one cats were enrolled. Local treatment response was evaluated as complete remission (CR), partial remission (PR) or stable disease (SD). Recurrence rate (RR), disease-free interval (DFI) and progression free survival (PFS) were calculated. A six-point scale was used for ECT toxicity. The median tumor size was 1.5 cm. CR was achieved in 65.6% of cases, PR in 31.1% and SD in 3.3%. The overall response rate was 96.7%, RR was 22.5%, median DFI was 136 days, and median PFS was 65.5 days. ECT toxicity was ≤2 in 51% of cats. Tumor recurrence/progression ( = 0.014) and local treatment response (PR: < 0.001; SD: < 0.001) influenced survival time. Cats with toxicity >2 showed a higher probability of tumor recurrence/progression. Tumor-related death was higher in cats with PR ( < 0.001) and recurrence/progression ( = 0.002), in ECT treatment with 1 Hz ( = 0.035) and 1200 V/cm ( = 0.011) or 1300 V/cm ( = 0.016). Tumor size influenced local treatment response ( = 0.008) and toxicity ( < 0.001). ECT is an effective treatment for feline npSCCs and should be considered as the first-line procedure for low-stage tumors.
猫鳞状细胞癌（SCC）目前采用手术、放射治疗和电化学疗法（ECT）进行治疗。对ECT作为单一疗法使用博来霉素治疗猫鼻平面SCC（npSCC）的疗效和/或安全性进行了评估。纳入了61只猫。局部治疗反应评估为完全缓解（CR）、部分缓解（PR）或疾病稳定（SD）。计算复发率（RR）、无病间期（DFI）和无进展生存期（PFS）。ECT毒性采用六点量表进行评估。肿瘤中位大小为1.5厘米。65.6%的病例达到CR，31.1%达到PR，3.3%为SD。总缓解率为96.7%，RR为22.5%，中位DFI为136天，中位PFS为65.5天。51%的猫ECT毒性≤2。肿瘤复发/进展（P = 0.014）和局部治疗反应（PR：P < 0.001；SD：P < 0.001）影响生存时间。毒性>2的猫肿瘤复发/进展的可能性更高。PR（P < 0.001）和复发/进展（P = 0.002）的猫、ECT治疗频率为1 Hz（P = 0.035）以及电压为1200 V/cm（P = 0.011）或1300 V/cm（P = 0.016）时，与肿瘤相关的死亡更高。肿瘤大小影响局部治疗反应（P = 0.008）和毒性（P < 0.001）。ECT是治疗猫npSCC的有效方法，对于低分期肿瘤应考虑作为一线治疗手段。
